Ion Channel Blockers for the Treatment of Neuropathic Pain

• IASP Council in Kyoto . IASP Terminology. Modified and improved for publication in Kyoto, Japan, 29–30November (2007).
   Google Scholar
• Gilron I , CoderreTJ. Emerging drugs in neuropathic pain.Exp. Opin. Emerg. Drugs12(1), 113–126 (2007).
   PubMed Web of Science ®Google Scholar
• Baron R . Mechanisms of disease: neuropathic pain – a clinical perspective.Nat. Clin. Pract.2(2), 95–106 (2006).
   Google Scholar
• Janig W , BaronR. Complex regional pain syndrome: mystery explained?Lancet Neurol.2, 687–697 (2003).
   PubMed Web of Science ®Google Scholar
• Marchand F , PerrettiM, McMahonSB. Role of the immune system in chronic pain.Nat. Rev. Neurosci.6, 521–532 (2005).
   PubMed Web of Science ®Google Scholar
• Petrenko AB , YamakuraT, BabaH, ShimojiK. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth. Analg.97(4), 1108–1116 (2003).
   PubMed Web of Science ®Google Scholar
• Qu XX , CaiJ, LiMJet al. Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain. Exp. Neurol. 215(2), 298–307 (2009).
   PubMed Web of Science ®Google Scholar
• Wieseler-Frank J , MaierSF, WatkinsLR. Central proinflammatory cytokines and pain enhancement.Neurosignals14, 166–174 (2005).
   PubMedGoogle Scholar
• Milligan ED , WatkinsLR. Pathological and protective roles of glia in chronic pain.Nat. Rev. Neurosci.10, 23–36 (2009).
   PubMed Web of Science ®Google Scholar
• Markman JD , DworkinRH. Ion channel targets and treatment efficacy in neuropathic pain.J. Pain7(1S), S38–S47 (2006).
   PubMedGoogle Scholar
• Matulenko MA , ScanioMJC, Kort,ME. Voltage-gated sodium channel blockers for the treatment of chronic pain.Curr. Top. Med. Chem.9, 362–376 (2009).
   PubMed Web of Science ®Google Scholar
• Burnstock G . Purinergic receptors and pain.Curr. Pharm. Des.15(15), 1717–1735 (2009).
   PubMed Web of Science ®Google Scholar
• Cortright DN , SzallasiA. TRP channels and pain.Curr. Pharm. Des.15(15),
   PubMed Web of Science ®Google Scholar
• Dubé GR , ElagozA, MangatH. Acid sensing ion channels and acid nociception.Curr. Pharm. Des.15(15), 1750–1766 (2009).
   PubMed Web of Science ®Google Scholar
• Dunlop J , VasilyevD, LuPet al. Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and pain. Curr. Pharm. Des. 15(15), 1767–1772 (2009).
   PubMed Web of Science ®Google Scholar
• Wickenden AD , McNaughton-SmithG. Kv7 channels as targets for the treatment of pain Curr. Pharm. Des.15(15), 1773–1798 (2009).
   PubMed Web of Science ®Google Scholar
• Dray A . Neuropathic pain: emerging treatments.Br. J. Anaesth.101(1), 48–58 (2008).
   PubMed Web of Science ®Google Scholar
• Dib-Hajj SD , BinshtokAM, CumminsTRet al. Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res. Rev. 60(1), 65–83 (2009).
   PubMedGoogle Scholar
• Catterall WA , GoldinAL, WaxmanSG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels.Pharmacol. Rev.57, 397–409 (2005).
   PubMed Web of Science ®Google Scholar
• Chahine M , ChatelierA, BabichOet al. Voltage-gated sodium channels in neurological disorders. CNS & Neurological Disorders – Drug Targets 7, 144–158 (2008).
   PubMed Web of Science ®Google Scholar
• Cummins TR , SheetsPL, WaxmanSG. The roles of sodium channels in nociception: implications for mechanisms of pain.Pain131(3), 243–257 (2007).
   PubMed Web of Science ®Google Scholar
• Priest BT . Future potential and status of selective sodium channel blockers for the treatment of pain.Curr. Opin. Drug Discov. & Develop.12(5), 682–692 (2009).
   PubMed Web of Science ®Google Scholar
• Waxman SG , KocsisJD, BlackJA. Type III sodium channel mRNA is expressed in embryonic but not in adult spinal sensory neurons, and is re-expressed following axotomy.J. Neurophysiol.72, 466–470 (1994).
   PubMed Web of Science ®Google Scholar
• Hains BC , KleinJP, SaabCYet al. Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J. Neurosci. 23, 8881–8892 (2003).
   PubMed Web of Science ®Google Scholar
• Hains BC , SaabCY, KleinJPet al. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J. Neurosci. 24, 4832–4839 (2004).
   PubMed Web of Science ®Google Scholar
• Coward K , AitkenA, PowellCet al. Plasticity of TTX-sensitive sodium channels PNI and brain III in injured human nerves. Neuroreport 12, 495–500 (2001).
   PubMed Web of Science ®Google Scholar
• Black JA , NikolajsenL, KronerKet al. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann. Neurol. 64(6), 644–653 (2008).
   PubMed Web of Science ®Google Scholar
• Cummins TR , WaxmanSG. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury.J. Neurosci.17, 3503–3514 (1997).
   PubMed Web of Science ®Google Scholar
• Cummins TR , AgliecoF, RenganathanM. et al. Na v1.3 sodium channels: rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons. J. Neurosci.21, 5952–5961 (2001).
   PubMed Web of Science ®Google Scholar
• Lampert A , HainsBC, WaxmanSG. Upregulation of persistent and ramp sodium current in dorsal horn neurons after spinal cord injury.Exp. Brain Res.174, 660–666 (2006).
   PubMed Web of Science ®Google Scholar
• Lindia JA , KohlerMG, MartinWJet al. Relationship between sodium channel Nav1.3 expression and neuropathic pain behavior in rats. Pain 117, 145–153 (2005).
   PubMed Web of Science ®Google Scholar
• Nassar MA , BakerMD, LevatoAet al. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol. Pain 2, 33 (2006).
   PubMed Web of Science ®Google Scholar
• Dib-Hajj SD , RushAM, CumminsTRet al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128(8), 1847–1854 (2005).
   PubMedGoogle Scholar
• Dib-Hajj SD , RushAM, CumminsTR, Waxman SG. Mutations in the sodium channel Nav1.7 underlie inherited erythromelalgia. Drug Discov. Today3(3), 343–350 (2006).
   Google Scholar
• Dib-Hajj SD , CumminsTR, BlackJA, WaxmanSG. From genes to pain: Nav1.7 and human pain disorders. Trends Neurosci.30(11), 555–563 (2007).
   PubMed Web of Science ®Google Scholar
• Drenth JP , WaxmanSG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J. Clin. Invest.117(12), 3603–3609 (2007).
   PubMed Web of Science ®Google Scholar
• Fertleman CR , BakerMD, ParkerKAet al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52, 767–774 (2006).
   PubMed Web of Science ®Google Scholar
• Cox JJ , ReimannF, NicholasAKet al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444, 894–898 (2006).
   PubMed Web of Science ®Google Scholar
• Goldberg Y , MacfarlaneJ, MacdonaldMet al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin. Genet. 71, 311–319 (2007).
   PubMed Web of Science ®Google Scholar
• Nassar MA , LevatoA, StirlingLCet al. Neuropathic pain develops normally in mice lacking both Nav1.7 and Nav1.8. Mol. Pain 1, 24 (2005).
   PubMed Web of Science ®Google Scholar
• Nassar MA , StirlingLC, ForlaniGet al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc. Natl. Acad. Sci. USA 101, 12706–12711 (2004).
   PubMed Web of Science ®Google Scholar
• Harty TP , Dib-HajjSD, TyrrellLet al. Nav1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons. J. Neurosci. 26, 12566–12575 (2006).
   PubMed Web of Science ®Google Scholar
• Rush AM , Dib-HajjSD, LiuSet al. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc. Natl. Acad. Sci. USA 103, 8245–8250 (2006).
   PubMed Web of Science ®Google Scholar
• Rush AM , CumminsTR, WaxmanSG. Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons.J. Physiol. (London)579(1), 1–14 (2007).
   Google Scholar
• Elliott AA , ElliottJR. Characterization of TTX-sensitive and TTX-resistant sodium currents in small cells from adult rat dorsal root ganglia.J. Physiol.463, 39–56 (1993).
   PubMed Web of Science ®Google Scholar
• Akopian AN , SouslovaV, EnglandSet al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat. Neurosci. 2, 541–548 (1999).
   PubMed Web of Science ®Google Scholar
• Renganathan M , CumminsTR, WaxmanSG. Contribution of Nav1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol.86, 629–640 (2001).
   PubMed Web of Science ®Google Scholar
• Black JA , LiuS, TanakaMet al. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 108, 237–247 (2004).
   PubMed Web of Science ®Google Scholar
• Gol MS , ReichlingDB, ShusterMJet al. Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in nociceptors. Proc. Natl. Acad. Sci. USA 93, 1108–1112 (1996).
   PubMed Web of Science ®Google Scholar
• Lai J , GoldMS, KimCSet al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, Nav1.8. Pain 95, 143–152 (2002).
   PubMed Web of Science ®Google Scholar
• Dib-Hajj S , BlackJA, FeltsPet al. Down-regulation of transcripts for Na channel α-SNS in spinal sensory neurons following axotomy. Proc. Natl. Acad. Sci. USA 93, 14950–14954 (1996).
   PubMed Web of Science ®Google Scholar
• Cummins TR , WaxmanSG. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury.J. Neurosci.17, 3503–3514 (1997).
   PubMed Web of Science ®Google Scholar
• Dib-Hajj SD , FjellJ, CumminsTRet al. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 83, 591–600 (1999).
   PubMed Web of Science ®Google Scholar
• Novakovic SD , TzoumakaE, McGivernJGet al. Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. J. Neurosci. 15, 18(6) 2174–2187 (1998).
   Google Scholar
• Gold M , WeinreichD, KimCSet al. Redistribution of Nav1.8 in uninjured axons enables neuropathic pain. J. Neurosci. 23, 158–166 (2003).
   PubMed Web of Science ®Google Scholar
• Cummins TR , Dib-HajjSD, BlackJAet al. A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory neurons. J. Neurosci. 19, RC43 (1999).
   PubMed Web of Science ®Google Scholar
• Roza C , LairdJMA, SouslovaVet al. The tetrodotoxin-resistant Na+ channel Nav1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J. Physiol. 550, 921–926 (2003).
   PubMed Web of Science ®Google Scholar
• Porreca F , LaiJ, BianDet al. A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc. Natl Acad. Sci. USA 96, 7640–7644 (1999).
   PubMed Web of Science ®Google Scholar
• Priest BT , MurphyBA, LindiaJAet al. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel Nav1.9 to sensory transmission and nociceptive behavior. Proc. Natl Acad. Sci. USA 102, 9382–9387 (2005).
   PubMed Web of Science ®Google Scholar
• Amaya F , WangH, CostiganMet al. The voltage-gated sodium channel Nav1.9 is an effector of peripheral inflammatory pain hypersensitivity. J. Neurosci. 26, 12852–12860 (2006).
   PubMed Web of Science ®Google Scholar
• Eisenberg E , RiverY, ShifrinAet al. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 67(9), 1265–1289 (2007).
   PubMed Web of Science ®Google Scholar
• Sindrup HJ , JensenTS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.Pain83, 389–400 (1999).
   PubMed Web of Science ®Google Scholar
• Campbell FG , GrahamJG, ZilkhaKJ. Clinical trial of carbazepine (Tegretol) in trigeminal neuralgia.J. Neurol. Neurosurg. Psychiatry29(3), 265–267 (1966).
   PubMed Web of Science ®Google Scholar
• Sindrup SH , JensenTS. Pharmacotherapy of trigeminal neuralgia.Clin. J. Pain18, 22–27 (2002).
   PubMed Web of Science ®Google Scholar
• Wilton TD . Tegretol in the treatment of diabetic neuropathy.S. Afr. Med. J.48(20), 869–872 (1974).
   PubMed Web of Science ®Google Scholar
• Gomez-Perez FJ , ChozaR, RiosJMet al. Nortriptyline–fluphenazine vs carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch. Med. Res. 27, 525–529 (1996).
   PubMed Web of Science ®Google Scholar
• Sindrup SJ , JensenTS. Are sodium channel blockers useless in peripheral neuropathic pain?Pain128, 6–7 (2007).
   PubMed Web of Science ®Google Scholar
• Bhattacharya A , WickendenAD, ChaplanSR. Sodium channel blockers for the treatment of neuropathic pain.Neurother.6(4), 663–678 (2009).
   PubMed Web of Science ®Google Scholar
• Cummins TR , RushAM. Voltage-gated sodium channel blockers for the treatment of neuropathic pain.Exp. Rev. Neurother.7(11), 1597–1612 (2007).
   PubMedGoogle Scholar
• Priest BT , KaczorowskiGJ. Blocking sodium channels to treat neuropathic pain.Expert Opin. Ther. Targets11(3), 291–306 (2007).
   PubMed Web of Science ®Google Scholar
• Jain KK . Current challenges and future prospects in management of neuropathic pain.Expert Rev. Neurother.8(11), 1743–1756 (2008).
   PubMedGoogle Scholar
• Bear B , AsgianJ, TerminA, ZimmermannN. Small molecules targeting sodium and calcium channels for neuropathic pain.Curr. Opin. Drug Discov. Develop.12(4), 543–561 (2009).
   PubMedGoogle Scholar
• Binshtok AM , BeanBP, WoolfCJ. Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers.Nature447, 607–611 (2007).
   Google Scholar
• Sah D , GuoW, LuoMet al. Small interfering RNA targeting Nav1.8 alleviates experimentally-induced chronic pain. Presented at: 36th Annual Meeting of the Society for Neuroscience. Atlanta, GA, USA, 14–18 October 2006 (Abstract 245.11).
   Google Scholar
• Catterall WA , Perez-ReyesE, SnutchTP, StriessnigJ. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels.Pharmacol. Rev.57(4), 411–425 (2005).
   PubMed Web of Science ®Google Scholar
• Cizkova D , MarsalaJ, LukacovaNet al. Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp. Brain Res. 147, 456–463 (2002).
   PubMed Web of Science ®Google Scholar
• Luo ZD , ChaplanSR, HigueraES et al. Upregulation of dorsal root ganglion (a)2(d) calcium channel subunit and its correlation with allodynia in spinal nerve injured rats. J. Neurosci.21(6), 1868–1875 (2001).
   PubMed Web of Science ®Google Scholar
• Striessnig J , KoschakA. Exploring the function and pharmacotherapeutic potential of voltage-gated Ca2+ channels with gene knockout models. Channels2(4), 1–19 (2008).
   PubMed Web of Science ®Google Scholar
• Kim C , JunK, LeeTet al. Altered nociceptive response in mice deficient in the a(1B) subunit of the voltage-dependent calcium channel. Mol. Cell. Neurosci. 18, 235–245 (2001).
   PubMed Web of Science ®Google Scholar
• Saegusa H , KuriharaT, ZongSet al. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J. 20, 2349–2356 (2001).
   PubMed Web of Science ®Google Scholar
• Williams JA , DayM, HeavnerJE. Ziconotide: an update and review.Expert Opin. Pharmacother.9(9), 1575–1583 (2008).
   PubMed Web of Science ®Google Scholar
• Vitale V , BattelliD, GasperoniE, MonacheseN. Intrathecal therapy with ziconotide: clinical experience and consideration on its use.Minerva Anestesiol.74, 727–733 (2008).
   PubMed Web of Science ®Google Scholar
• Moore RA , StraubeS, WiffenPJ, DerryS, McQuayHJ. Pregabalin for acute and chronic pain in adults.Cochrane Database Syst. Rev.8(3), CD007076 (2009).
   Google Scholar
• Noor M , GajrajNM. Pregabalin: its pharmacology and use in pain managementAnesth. Analg.105(6), 1805–1815 (2007).
   PubMed Web of Science ®Google Scholar
• McKeage K , KeamSJ. Pregabalin: in the treatment of postherpetic neuralgia.Drugs Aging26(10), 883–892 (2009).
   PubMed Web of Science ®Google Scholar
• Taylor CP . Mechanisms of analgesia by gabapentin and pregabalin calcium channel α2-δ [Cavα2-δ] ligands. Pain142(1–2), 13–16 (2009).
   PubMed Web of Science ®Google Scholar
• Davies A , HendrichJ, Tran Van Minh A, Wratten J, Douglas L, Dolphin AC. Functional biology of the α2-δ subunits of voltage-gated calcium channels. Trends Pharmacol. Sci.28(5), 220–228 (2007).
   PubMed Web of Science ®Google Scholar
• Heblich F , Tran Van Minh A, Hendrich J, Watschinger K, Dolphin AC. Time course and specificity of the pharmacological disruption of the trafficking of voltage-gated calcium channels by gabapentin. Channels2(1), 4–9 (2008).
   PubMedGoogle Scholar
• Perez-Reyes E . Molecular physiology of low-voltage-activated T-type calcium channels.Physiol. Rev.83, 117–161, (2003).
   PubMed Web of Science ®Google Scholar
• Jagodic MM , PathirathnaS, JoksovicPMet al. Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J. Neurophysiol. 99, 3151–3156 (2008).
   PubMed Web of Science ®Google Scholar
• Jagodic MM , PathirathnaS, NelsonMTet al. Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J. Neurosci. 27(12), 3305–3316 (2007).
   PubMed Web of Science ®Google Scholar
• Todorovic SM , Jevtovic-TodorovicV. Regulation of T-type channels in the peripheral pain pathway.Channels4, 238–245 (2007).
   Google Scholar
• McCallum JB , KwokWM, MynlieffM, BosnjakZJ, HoganQH. Loss of T-type calcium current in sensory neurons of rats with neuropathic pain.Anesthesiology98, 209–216 (2003).
   PubMed Web of Science ®Google Scholar
• Wolfart J , RoeperJ. Selective coupling of T-type calcium channels to SK potassium channels prevents intrinsic bursting in dopaminergic midbrain neurons.J. Neurosci.22, 3404–3413 (2002).
   PubMed Web of Science ®Google Scholar
• Mircea C . Iftinca MC, Zamponi GW. Regulation of neuronal T-type calcium channels.Trends Pharmacol. Sci.30(1), 32–40 (2009).
   PubMed Web of Science ®Google Scholar
• Bourinet E , AllouiA, MonteiolAet al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J. 24, 315–324 (2005).
   PubMed Web of Science ®Google Scholar
• Belardetti F , ZamponiGW. Linking calcium channel isoforms to potential therapiesCurr. Opin. Invest. Drugs7, 707–715 (2008).
   Google Scholar
• Gajraj NM . Pregabalin: its pharmacology and use in pain management.Anesth. Analg.6, 1805–1815 (2007).
   Google Scholar
• Kolosov A , GoodchildCS, CookIet al. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 11, 262–273 (2010).
   PubMed Web of Science ®Google Scholar
• Yamamoto T , TakaharaA. Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke.Curr. Top. Med. Chem.9, 377–395 (2009).
   PubMed Web of Science ®Google Scholar
• Gutman GA , ChandyKG, GrissmerSet al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol. Rev. 57, 473–508 (2005).
   PubMed Web of Science ®Google Scholar
• Wei AD , GutmanGA, AldrichRet al. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol. Rev. 57, 463–472 (2005).
   PubMed Web of Science ®Google Scholar
• Kubo Y , AdelmanJP, ClaphamDEet al. International Union of Pharmacology. LIV. Nomenclature and molecular relationships of inwardly rectifying potassium channels. Pharmacol. Rev. 57, 509–526 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein SAN , BaylissDA, KimDet al. International Union of Pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels. Pharmacol. Rev. 57, 527–540 (2005).
   PubMed Web of Science ®Google Scholar
• Ocana M , CendanCM, CobosEJ, EntrenaJM, Baeyens,JM. Potassium channels and pain: present realities and future opportunities.Eur. J. Pharmacol.500, 203–219 (2004).
   PubMed Web of Science ®Google Scholar
• Chien L -Y, Cheng J-K, Chu D, Cheng C-F, Tsaur M-L. Reduced expression of A-type potassium channels in primary sensory neurons induces mechanical hypersensitivity. J. Neurosci.27(37), 9855–9865 (2007).
   PubMed Web of Science ®Google Scholar
• Phuket N , RatanadilokT, CovarrubiasM. Kv4 channels underlie the subthreshold-operating A-type K-current in nociceptive dorsal root ganglion neurons. Front. Mol. Neurosci.2, 3 (2009).
   PubMed Web of Science ®Google Scholar
• Chen SR , CaiYQ, PanHL. Plasticity and emerging role of BKCa channels in nociceptive control in neuropathic pain.J. Neurochem.110(1), 352–362 (2009).
   PubMed Web of Science ®Google Scholar
• Rivera-Arconada I , RozaC, Lopez-GarciaJA. Enhancing M currents: a way out for neuropathic pain?Front Mol Neurosci.2, 10 (2009).
   PubMed Web of Science ®Google Scholar
• Jiang YQ , SunQ, TuHY, WanY. Characteristic of HCN channels and their participation in neuropathic pain.Neurochem. Res.33, 1979–1989 (2008).
   PubMed Web of Science ®Google Scholar
• Noma A , IrisawaH. Membrane currents in the rabbit sinoatrial node cell as studied by the double microelectrode method.Pflugers Arch.364(1), 45–52 (1976)
   PubMed Web of Science ®Google Scholar
• Chaplan SR , GuoHQ, LeeDHet al. Neuronal hyperpolarization-activated pacemaker channels drive neuropathic pain. J.Neurosci. 23, 1169–1178 (2003).
   PubMed Web of Science ®Google Scholar
• Sun Q , XingGG, TuHY, HanJS, WanY. Inhibition of hyperpolarization-activated current by ZD7288 suppresses ectopic discharges of injured dorsal root ganglion neurons in a rat model of neuropathic pain.Brain Res.1032(1–3), 63–69 (2005).
   PubMed Web of Science ®Google Scholar
• Mayer ML , WestbrookGL. A voltage-clamp analysis of inward (anomalous) rectification in mouse spinal sensory ganglion neurones.J.Physiol.340, 19–45 (1983).
   PubMed Web of Science ®Google Scholar
• Kouranova EV , StrassleBW, RingRH, BowlbyMR, VasilyevDV. Hyperpolarization-activated cyclic nucleotide-gated channel mRNA and protein expression in large versus small diameter dorsal root ganglion neurons: correlation with hyperpolarization-activated current gating.Neuroscience153(4), 1008–1019 (2008).
   PubMed Web of Science ®Google Scholar
• Tu H , DengL, SunQ, YaoL, HanJS, WanY. Hyperpolarization-activated, cyclic nucleotide-gated cation channels: roles in the differential electrophysiological properties of rat primary afferent neurons.J. Neurosci. Res.76(5), 713–722 (2004).
   PubMed Web of Science ®Google Scholar
• Papp I , SzucsP, HolloK, ErdelyiF, SzaboG, AntalM. Hyperoplarization-activated and cyclic nucleotide-gated cation channel subunit 2 ion channels modulate synaptic transmission from nociceptive primary afferents containing substance P to secondary sensory neurons in laminae I-IIo of the rodent spinal dorsal horn. Eur. J. Neurosci.24, 1341–1352 (2006).
   PubMed Web of Science ®Google Scholar
• Luo L , ChangL, BrownSMet al. Role of peripheral hyperpolarization-activate cyclic nucleotide-modulated channel pacemaker channels in acute and chronic pain models in the rat. Neuroscience 144, 1477–1485 (2007).
   PubMed Web of Science ®Google Scholar
• Bie B , PengY, ZhangY, PanZZ. cAMP-mediated mechanism for pain sensitization during opioid withdrawal.J. Neurosci.25(15), 3824–3832 (2005).
   PubMed Web of Science ®Google Scholar
• Jolas T , NestlerEJ, AghajanianGK. Chronic morphine increases GABA tone on serotoninergic neurons of the dorsal raphe nucleus: association with an upregulation of the cyclic AMP pathway.Neuroscience95(2), 433–443 (2000).
   PubMed Web of Science ®Google Scholar
• Brown SM , DubinAE, ChaplanSR. The role of pacemaker currents in neuropathic pain.Pain Practice4(3), 182–193 (2004).
   PubMedGoogle Scholar
• Devor M , RaberP. Autotomy after nerve injury and its relation to spontaneous discharge originating in nerve-end neuromas.Behav. Neurol. Biol.37, 276–283 (1983).
   PubMedGoogle Scholar
• Liu CN , WallPD, Ben-DorE, MichaelisM, AmirR, DevorM. Tactile allodynia in the absence of C-fiber activation: altered firing properties of DRG neurons following spinal nerve injury.Pain85, 503–521 (2000).
   PubMed Web of Science ®Google Scholar
• Tal M , EliavE. Abnormal discharge originates at the site of nerve injury in experimental constriction neuropathy (CCI) in the rat.Pain64(3), 511–518 (1996).
   PubMed Web of Science ®Google Scholar
• Kajander KC , BennettGJ. Onset of a painful peripheral neuropathy in rat: a partial and differential deafferentation and spontaneous discharge in A-β and A-δ primary afferent neurons.J. Neurophysiol.68(3), 734–744 (1992).
   PubMed Web of Science ®Google Scholar
• Song XJ , HuSJ, GreenquistKW, ZhangJM, LaMotteRH. Mechanical and thermal hyperalgesia and ectopic neuronal discharge after chronic compression of dorsal root ganglia.J.Neurophysiol.82(6), 3347–3358 (1999).
   PubMed Web of Science ®Google Scholar
• Wan Y . Involvement of hyperpolarization-activated cyclic nucleotide-gated cation channels in dorsal root ganglion in neuropathic pain.Acta Physiol. Sinica60(5), 579–580 (2008).
   PubMedGoogle Scholar
• Yao H , DonnellyDF, MaC, LaMotteRH. Upregulation of the hyperpolarization-activated cation current after chronic compression of the dorsal root ganglion.J. Neurosci.23, 2069–2074 (2003).
   PubMed Web of Science ®Google Scholar
• Jiang YQ , XingGG, WangSLet al. Axonal accumulation of hyperpolarization-activated cyclic nucleotide-gated cation channels contributes to mechanical allodynia after peripheral nerve injury in rat. Pain 137, 495–506 (2008).
   PubMed Web of Science ®Google Scholar
• Lee DH , ChangL, SorkinLS, ChaplanSR. Hyperpolarization-activated, cation-nonselective, cyclic nucleotide-modulated channel blockade alleviates mechanical allodynia and suppresses ectopic discharge in spinal nerve ligated rats.J.Pain.6(7), 417–424 (2005).
   PubMed Web of Science ®Google Scholar
• Hellwig N , AlbrechN, HarteneckC, SchultzG, SchaeferM. Homo- and heteromeric assembly of TRPV channel subunits.J. Cell Sci.118, 917–928 (2005).
   PubMed Web of Science ®Google Scholar
• Salazar H , Jara-OsegueraA, Hernandez-GarciaEet al. Structural determinants of gating in the TRPV1 channel. Nat. Struct. Mol. Biol. 16(7), 704–710 (2009).
   PubMed Web of Science ®Google Scholar
• Montell C . The TRP superfamily of cation channels.Science STKE272, re3 (2005).
   Google Scholar
• Caterina MJ , SchumacherMA, TominagaM, RosenTA, LevineJD, JuliusD. The capsaicin receptor: a heat-activated ion channel in the pain pathway.Nature389, 816–824 (1997).
   PubMed Web of Science ®Google Scholar
• Tominaga M , CaterinaMJ, MalmbergABet al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21, 531–543 (1998).
   PubMed Web of Science ®Google Scholar
• Xu H , BlairNT, ClaphamDE. Camphor activates and strongly desensitizes the transient receptor potential vanilloid subtype 1 channel in a vanilloid-independent mechanism.J. Neurosci.25, 8924–8937 (2005).
   PubMed Web of Science ®Google Scholar
• Macpherson LJ , GeierstangerBH, ViswanathVet al. The pungency of garlic: activation of TRPA1 and TRPV1 in response to allicin. Curr. Biol. 15, 929–934 (2005).
   PubMed Web of Science ®Google Scholar
• Yoshida T , InoueR, MoriiTet al. Nitric oxide activates TRP channels by cysteine S-nitrosylation. Nat. Chem. Biol. 2(11), 596–607 (2006).
   PubMed Web of Science ®Google Scholar
• Trevisani M , SmartD, GunthorpeMJet al. Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat. Neurosci. 5, 546–551 (2002).
   PubMed Web of Science ®Google Scholar
• Lee SY , LeeJH, KangKK, HwangSY, ChoiKD, OhU. Sensitization of vanilloid receptor involves an increase in the phosphorylated form of the channel.Arch. Pharm. Res.28, 405–412 (2005).
   PubMed Web of Science ®Google Scholar
• Sanchez JF , KrauseJE, CortrightDN. The distribution and regulation of vanilloid receptor VR1 and VR1 5´ splice variant RNA expression in rat.Neuroscience107, 373–381 (2001).
   PubMed Web of Science ®Google Scholar
• Caterina MJ , JuliusD. The vanilloid receptor: a molecular gateway to the pain pathway.Annu. Rev. Neurosci.24, 487–517 (2001).
   PubMed Web of Science ®Google Scholar
• Hudson LJ , BevanS, WotherspoonG, GentryC, FoxA, WinterJ. VR1 protein expression increases in undamaged DRG neurons after partial nerve injury.Eur. J. Neurosci.13, 2105–2114 (2001).
   PubMed Web of Science ®Google Scholar
• Caterina MJ , LefflerA, MalmbergABet al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288, 306–313 (2000).
   PubMed Web of Science ®Google Scholar
• Davis JB , GrayJ, GunthorpeMJet al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405, 183–187 (2000).
   PubMed Web of Science ®Google Scholar
• Christoph T , GillenC, MikaJet al. Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1. Neurochem. Int. 50, 281–290 (2007).
   PubMed Web of Science ®Google Scholar
• Christoph T , GrunwellerA, MikaJet al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem. Biophys. Res. Commun. 350, 238–243 (2006).
   PubMed Web of Science ®Google Scholar
• Kanai Y , NakazatoE, FujiuchiA, HaraT, ImaiA. Involvement of an increased spinal TRPV1 sensitization through its upregulation in mechanical allodynia of CCI rats.Neuropharmacol.49, 977–984 (2005).
   PubMed Web of Science ®Google Scholar
• Pomonis JD , HarrisonJE, MarkL, BristolDR, ValenzanoKJ, WalkerK. N-4-Tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a novel, orally-effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther.306, 387–393 (2003).
   PubMed Web of Science ®Google Scholar
• Honore P , WismerCT, MikusaJet al. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J. Pharmacol. Exp. Ther. 314, 410–421 (2005).
   PubMed Web of Science ®Google Scholar
• Smith GD , GunthorpeMJ, KelsellREet al. TRPV3 is a temperature sensitive vanilloid receptor-like protein. Nature 418, 186–190 (2002).
   PubMed Web of Science ®Google Scholar
• Xu H , RamseyIS, KotechaSAet al. TRPV3 is a calcium-permeable temperature-sensitive cation channel. Nature 418, 181–186 (2002).
   PubMed Web of Science ®Google Scholar
• Hu HZ , XiaoR, WangCet al. Potentiation of TRPV3 channel function by unsaturated fatty acids. J. Cell. Physiol. 208, 201–212 (2006).
   PubMed Web of Science ®Google Scholar
• Peier AM , ReeveAJ, AnderssonDAet al. A heat-sensitive TRP channel expressed in keratinocytes. Science 296, 2046–2049 (2002).
   PubMed Web of Science ®Google Scholar
• Moqrich A , HwangSW, EarleyTJet al. Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science 307, 1468–1472 (2005).
   PubMed Web of Science ®Google Scholar
• Gullapalli S , ThomasA, RaoP, KattigeV, GudiGS, Khairatkar-JoshiN. GRC-15133: a novel, selective TRPV3 antagonist with antihyperalgesic effects in inflammatory and neuropathic pain. CHI’s World Pharmaceutical Congress, Philadelphia, PA, USA, 2008.
   Google Scholar
• Jaquemar D , Schenker, Trueb B. An ankyrin-like protein with transmembrane domains is specifically lost after oncogenic transformation of human fibroblasts. J. Biol.Chem.274, 7325–7333 (1999).
   PubMed Web of Science ®Google Scholar
• Bandell M , StoryGM, HwangSWet al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41, 849–857 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor-Clark TE , UndemBJ, MacglashanDW, GhattaS, CarrMJ, McAlexanderMA. Prostaglandin-induced activation of nociceptive neurons via direct interaction with transient receptor potential A1 (TRPA1).Mol. Pharmacol.73, 274–281 (2008).
   PubMed Web of Science ®Google Scholar
• Story GM , PeierAM, ReeveAJ, EidSR, MosbackerJ, HricikTR. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures.Cell112, 819–829 (2003).
   PubMed Web of Science ®Google Scholar
• Obata K , KatsuraH, MizushimaT, YamanakaH, KobayashiK, DayY. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury.J. Clin. Invest.115, 2393–2401 (2005).
   PubMed Web of Science ®Google Scholar
• Bautista DM , JordtSE, NikaiT, TsurudaPR, ReadAJ, PobleteJ. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents.Cell124, 1269–1282 (2006).
   PubMed Web of Science ®Google Scholar
• Katsura H , ObataK, MizushimaT, YamanakaH, KobayashiK, DayY. Antisense knock-down of TRPA1, but not TRPM8, alleviates cold hyperalgesia after spinal nerve ligation in rats.Exp. Neurol.200, 112–113 (2006).
   PubMed Web of Science ®Google Scholar
• Jane DE , LodgeD, CollingridgeGL. Kainate receptors: pharmacology, function and therapeutic potential.Neuropharmacol.56, 90–113 (2009).
   PubMed Web of Science ®Google Scholar
• Petrus M , PeierAM, BandellMet al. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol. Pain 3, 40 (2007).
   PubMed Web of Science ®Google Scholar
• McNamara CR , Mandel BrehmJ, BautistaDMet al. TRPA1 mediates formalin-induced pain. Proc. Natl. Acad. Sci. USA104, 13525–13530 (2007).
   PubMed Web of Science ®Google Scholar
• Eid SR , CrownED, MooreELet al. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol. Pain 4, 48 (2008).
   PubMed Web of Science ®Google Scholar
• Peier AM , MoqrichA, HergardenAC, ReeveAJ, AnderssonDA, StoryGM. A TRP channel that senses cold stimuli and menthol.Cell108, 705–715 (2002).
   PubMed Web of Science ®Google Scholar
• Bautista DM , SiemensJ, GlazerJM, TsurudaPR, BasbaumAI, StuckyCL. The menthol receptor TRPM8 is the principal detector of environmental cold.Nature448, 204–208 (2007).
   PubMed Web of Science ®Google Scholar
• McKemy DD , NeuhausserWM, JuliusD. Identification of a cold receptor reveals a general role for TRP channels in thermosensation.Nature416, 52–58 (2007).
   Google Scholar
• Kobayashi A , FukuokaT, ObataHet al. Distinct expression of TRPM8, TRPA1 and TRPV1 mRNAs in rat primary afferent neurons with Aδ/C-fibers and colocalization with Trk receptors. J. Comp. Neurol. 493, 596–606 (2005).
   PubMed Web of Science ®Google Scholar
• Colburn RW , LubinML ., Stone DJ, Wang Y, Lawrence D, D‘Andrea MR. Attenuated cold sensitivity in TRPM8 null mice. Neuron54, 379–386 (2007).
   PubMed Web of Science ®Google Scholar
• Dhaka A , MurrayAN, MathurJ, EarleyTJ, PetrusMJ, PatapoutianA. TRPM8 is required for cold sensation in mice.Neuron54, 371–378 (2007).
   PubMed Web of Science ®Google Scholar
• Proudfoot CJ , GarryEM, CottrellDFet al. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr. Biol. 16, 1591–1605 (2006).
   PubMed Web of Science ®Google Scholar
• Xing H , ChenM, LingJ, TanW, GuJG. TRPM8 mechanism of cold allodynia after chronic nerve injury.J. Neurosci.27, 13680–13690 (2007).
   PubMed Web of Science ®Google Scholar
• Caspani O , ZurborgS, LabuzD, HeppenstallPA. The contribution of TRPM8 and TRPA1 channels to cold allodynia and neuropathic pain.PloS ONE4(10), e7383 (2009).
   PubMed Web of Science ®Google Scholar
• Szallasi A , AppendinoG. Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse?J. Med. Chem.47(11), 2717–2723 (2004).
   PubMed Web of Science ®Google Scholar
• Westaway SM . The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.J. Med. Chem.50, 2589–2596 (2007).
   PubMed Web of Science ®Google Scholar
• Szallasi A , CortrightDN, BlumCA, EidSR. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.Nat. Rev. Drug Discov.6, 357–372 (2007).
   PubMed Web of Science ®Google Scholar
• Starowicz K , CristinoL, DiMarzoV. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications.Curr. Phar. Des.14, 42–54 (2008).
   PubMed Web of Science ®Google Scholar
• Wong GY , GavvaNR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks.Brain Res. Rev.60, 267–277 (2009).
   PubMed Web of Science ®Google Scholar
• Gavva NR . Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1.Trends. Pharm. Sci.29(11), 550–557 (2008).
   PubMed Web of Science ®Google Scholar
• Salter M .W. Cellular signaling pathways of spinal pain neuroplasticity as targets for analgesic development. Curr. Top. Med. Chem.5, 557–567 (2005).
   PubMed Web of Science ®Google Scholar
• Bleakman D , AltA, NisenbaumES. Glutamate receptors and pain.Semin. Cell. Dev. Biol.17, 592–604 (2007).
   Web of Science ®Google Scholar
• Collingridge GL , OlsenRW, PetersJ, SpeddingM. A nomenclature for ligand-gated ion channels.Neuropharmacol.56, 2–5 (2009).
   PubMed Web of Science ®Google Scholar
• Mayer ML , ArmstrongN. Structure and function of glutamate receptor ion channels.Annu. Rev. Physiol.66, 161–181 (2004).
   PubMed Web of Science ®Google Scholar
• Paoletti P , NeytonJ. NMDA receptor subunits: function and pharmacology.Curr. Opin. Pharmacol.7(1), 39–47 (2007).
   PubMed Web of Science ®Google Scholar
• Childers WE Jr, Baudy RB. N-methyl-D-aspartate antagonists and neuropathic pain: the search for relief. J. Med. Chem.50(11), 2557–2562 (2007).
   PubMed Web of Science ®Google Scholar
• Yaksh TL , SorkinLS. Mechanism of neuropathic pain.Curr. Med. Chem. CNS Agents11, 2977–2994 (2005).
   Google Scholar
• Zhou S , BonaseraL, CarltonSM. Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats.Neuroreport7, 895–900 (1996).
   PubMed Web of Science ®Google Scholar
• Coderre TJ , MelzackR. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury.J.Neurosci.12, 3665–3670 (1992).
   PubMed Web of Science ®Google Scholar
• Karlsson U , SjodinJ, AngebyKet al. Glutamate-induced currents reveal three functionally distinct NMDA receptor populations in rat dorsal horn. Effects of pheriperal nerve lesion and inflammation. Neuroscience 112, 861–868 (2002).
   PubMed Web of Science ®Google Scholar
• Davies SN , LodgeD. Evidence for involvement of N-methylaspartate receptors in “windup” of class 2 neurones in the dorsal horn of the rat. Brain Res.424, 402–406 (1987).
   PubMed Web of Science ®Google Scholar
• Dickenson AH , SullivanAF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurons following C fibre stimulation.Neuropharmacol.26, 1235–1238 (1987).
   PubMed Web of Science ®Google Scholar
• Brown DG , KruppJJ. N methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics. Curr. Top. Med. Chem.6, 749–770 (2006).
   PubMed Web of Science ®Google Scholar
• Chizh BA , HeadleyPM. NMDA antagonists and neuropathic pain – multiple drug targets and multiple uses.Curr. Pharm. Des.11, 2977–2994 (2005).
   PubMed Web of Science ®Google Scholar
• Mony L , KewJNC, GunthorpeMJ, PaolettiP. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanism and therapeutic potential.Br. J. Pharmacol.157, 1301–1317 (2009).
   PubMed Web of Science ®Google Scholar
• Morales-Alcelay S , RubioL, MartinezA. AMPA glutamate receptors and neuropathic pain.Minirev. Med. Chem.3, 757–763 (2003).
   Web of Science ®Google Scholar
• Garry EM , MossA, RosieRet al. Specific involvement in neuropathic pain of AMPA receptors and adapter proteins for the GluR2 subunit. Mol. Cell. Neurosci. 24, 10–22 (2003).
   PubMed Web of Science ®Google Scholar
• Harris JA , CorsiM, QuartiroliM, ArbanR, BentivoglioM. Upregulation of spinal glutamate receptors in chronic pain.Neuroscience74, 7–12 (1996).
   PubMed Web of Science ®Google Scholar
• Bennett AD , EverhartAW, HulseboschCE. Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury.Brain Res.859, 72–82 (2000).
   PubMed Web of Science ®Google Scholar
• Szekely JI , TorokK, MatéG. The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding site.Curr. Pharm. Des.8, 887–912 (2002).
   PubMed Web of Science ®Google Scholar
• Donevan SD , RogawskiMA. GYKI52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses.Neuron10, 51–59 (1993).
   PubMed Web of Science ®Google Scholar
• Gilron I , MaxMB, LeeGet al. Effects of the 2-amino-3-hydroxy-5-methyl-4-isoazole-propionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin. Pharmacol. Ther. 68, 320–327 (2000).
   PubMed Web of Science ®Google Scholar
• Gormsen L , FinnerupNB, AlmqvistPM, JensenTS. The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study.Anesth. Analg.108, 1311–1319 (2009).
   PubMed Web of Science ®Google Scholar
• Sato K , KiyamaH, ParkHT, TohyamaM. AMPA, KA and NMDA receptors are expressed in the rat DRG neurons.Neuroreport4, 1263–1265 (1993).
   PubMed Web of Science ®Google Scholar
• Giovengo SL , KittoKF, KurtzHJ, VelazquezRA, LarsonAA. Parenterally administered kainic acid induces a persistent hyperalgesia in the mouse and rat.Pain111, 151–161 (1999).
   Google Scholar
• Procter MJ , HoughtonAK, FaberESet al. Actions of kainate and AMPA selective glutamate receptor ligands on nociceptive processing in the spinal cord. Neuropharmacol. 37, 1287–1297 (1998).
   PubMed Web of Science ®Google Scholar
• Alt A , WeissB, OgdenAMet al. Pharmacological characterization of glutamatergic agonist and antagonist at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacol. 46, 793–806 (2004).
   PubMed Web of Science ®Google Scholar
• Palecek J , NeugebauerV, CarltonSM, IvengarS, WillisWD. The effect of kainate GluR5 receptor antagonist on responses of spinothalamic neurons in a model of peripheral neuropathy in primates.Pain111, 151–161 (2004).
   PubMed Web of Science ®Google Scholar
• Wu L , KoSW, ZhuoM. Kainate receptors and pain: from dorsal root ganglion to the anterior cingulated cortex.Curr. Pharm. Des.13, 1597–1605 (2007).
   PubMed Web of Science ®Google Scholar
• Burnstock G . Physiology and pathophysiology of purinergic neurotransmission.Physiol. Rev.87, 659–797 (2007).
   PubMed Web of Science ®Google Scholar
• Burnstock G , WilliamsM. P2 purinergic receptors: modulation of cell function and therapeutic potential.J. Pharmacol. Exp.295, 862–869 (2000).
   PubMed Web of Science ®Google Scholar
• North RA . Molecular physiology of P2X receptors.Physiol. Rev.82, 1013–1067 (2002).
   PubMed Web of Science ®Google Scholar
• Khakh BS , NorthRA. P2X receptors as cell-surface ATP sensors in health and disease.Nature442, 527–532 (2006).
   PubMed Web of Science ®Google Scholar
• North RA , SuprenantA. Pharmacology of cloned P2X receptors.Annu. Rev. Pharmacol. Toxicol.40, 563–580 (2000).
   PubMed Web of Science ®Google Scholar
• Fredholm BB , IjzermanAP, JacobsonKA, KlotzKN, LindenJ. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.Pharmacol. Rev.53, 527–552 (2001).
   PubMed Web of Science ®Google Scholar
• Burnstock G . Purine and pyrimidine receptors.Cell. Mol. Life Sci.64, 1471–1483 (2007).
   PubMed Web of Science ®Google Scholar
• Guo C , MasinM, QureshiOS, Murrell-LagnadoRD. Evidence for functional P2X4/P2X7 heteromeric receptors. Mol. Pharmacol.72, 1447–1456 (2007).
   PubMed Web of Science ®Google Scholar
• Jones CA , VialC, SellersLAet al. Functional regulation of P2X6 receptors by N-linked glycosylation: identification of novel α:β-methylene ATP-sensitive phenotype. Mol. Pharmacol. 65(4), 979–985 (2004).
   PubMed Web of Science ®Google Scholar
• Holton FA , HoltonPJ. The capillary dilator substances in dry powders of spinal roots; a possible role for adenosine triphosphate in chemical transmission from nerve endings.J. Physiol.126, 124–140 (1954).
   PubMed Web of Science ®Google Scholar
• Holton PJ . The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves.J. Physiol.145, 494–504 (1959).
   PubMed Web of Science ®Google Scholar
• Jahr CE , JessellTM. ATP excites a subpopulation of rat dorsal horn neurones.Nature304, 730–733 (1983).
   PubMed Web of Science ®Google Scholar
• Nakagawa T ,Wakamatsu K, Zhang N et al. Intrathecal administration of ATP produces long-lasting allodynia in rats: differential mechanisms in the phase of the induction and maintenance. Neuroscience147, 445–455 (2007).
   PubMed Web of Science ®Google Scholar
• Bleehen T , KeeleCA. Observation on the algogenic actions of adenosine compounds on the human blister base preparation.Pain3, 367–377 (1977).
   PubMed Web of Science ®Google Scholar
• Hamilton SG , WarburtonJ, BhattacharjeeA, WardJ, McMahonSB. ATP in human skin elicits a dose-related pain response under conditions of hyperalgesia.Brain123, 1238–1246 (2000).
   PubMed Web of Science ®Google Scholar
• Jarvis MF . Contributions of P2X3 homomeric and heteromeric channels to acute and chronic pain. Exp. Opin. Ther. Targets7, 513–522 (2003).
   PubMed Web of Science ®Google Scholar
• Inoue K . The function of microglia through purinergic receptors: neuropathic pain and cytokine release.Pharmacol. Ther.109, 210–226 (2006).
   PubMed Web of Science ®Google Scholar
• Donnelly-Roberts D , McGaraughtyS, ShiehCC, HonoreP, JarvisMF. Painful purinergic receptors.J. Pharmaol. Exp. Ther.324, 409–415 (2008).
   PubMed Web of Science ®Google Scholar
• Ahrens J , LeuwerM, ReyhanDet al. Positive allosteric modulatory effects of ajulemic acid at strychnine-sensitive glycine α1- and α1β-receptors. Naunyn Schmied. Arch. Pharmacol. 379(4), 371–378 (2009).
   PubMed Web of Science ®Google Scholar
• Burnstock G . Purine-mediated signalling in pain and visceral perception.Trends Pharmacol. Sci.22, 182–188 (2001).
   PubMed Web of Science ®Google Scholar
• Shinoda M , KawashimaK, OzakiN, AsaiH, NagamineK, SugiuraY. P2X3 receptor mediates heat hyperalgesia in a rat model of trigeminal neuropathic pain. J. Pain8, 588–597 (2007).
   PubMed Web of Science ®Google Scholar
• Cockayne DA , HamiltonSG, ZhuQMet al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407, 1011–1015 (2000).
   PubMed Web of Science ®Google Scholar
• Souslova V , CesareP, DingYet al. Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature 407, 1015–1017(2000).
   PubMed Web of Science ®Google Scholar
• Honore P , KageK, MikusaJet al. Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain 99, 11–19 (2002).
   PubMed Web of Science ®Google Scholar
• Dorn G , PatelS, WotherspoonGet al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32, e49 (2004).
   PubMed Web of Science ®Google Scholar
• Honore P , MikusaJ, BianchiBet al. TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics. Pain 96, 99–105 (2002).
   PubMed Web of Science ®Google Scholar
• Kim C , ChungJM, ChungK. Changes in the gene expression of six subtypes of P2X receptors in rat dorsal root ganglion after spinal nerve ligation.Neurosci. Lett.337, 81–84 (2003).
   PubMed Web of Science ®Google Scholar
• Inoue K . The function of microglia through purinergic receptors: neuropathic pain and cytokine release.Pharmacol. Ther.109, 210–226 (2006).
   PubMed Web of Science ®Google Scholar
• Surprenant A , RassendrenF, KawashimaE, NorthRA, BuellG. The cytolytic P2z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science272, 735–738 (1996).
   PubMed Web of Science ®Google Scholar
• Nuttle LC , DubyakGR. Differential activation of cation channels and non-selective pores by macrophage P2z purinergic receptors expressed in Xenopus oocytes.J. Biol. Chem.269(19), 13988–13996 (1994).
   PubMed Web of Science ®Google Scholar
• Hide I , TanakaM, InoueAet al. Extracellular ATP triggers tumor necrosis factor-α release from rat microglia. J. Neurochem. 75, 965–972 (2000).
   PubMed Web of Science ®Google Scholar
• Sanz JM , Di Virgilio F. Kinetics and mechanism of ATP-dependent IL-1 β release from microglial cells. J. Immunol.164, 4893–4898 (2000).
   PubMed Web of Science ®Google Scholar
• Watkins LR , MilliganED, MaierSF. Glial activation: a driving force for pathological pain.Trends Neurosci.24:450– 455 (2001).
   PubMed Web of Science ®Google Scholar
• Papp L , ViziES, SperlághB. Lack of ATP-evoked GABA and glutamate release in the hippocampus of P2X7 receptor -/- mice. Neuroreport15, 2387–2391 (2004).
   PubMed Web of Science ®Google Scholar
• Chessell IP , HatcherJP, BountraCet al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114:386–396 (2005).
   PubMed Web of Science ®Google Scholar
• Honore P , Donnelly-RobertsD, NamovicMTet al. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino)methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl) acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J. Pharmacol. Exp. Ther. 319:1376–1385 (2006).
   PubMed Web of Science ®Google Scholar
• Lingueglia E . Acid-sensing ion channels in sensory perception.J.Biol.Chem.282(24), 17325–17329 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzales EB , KawateT, GouauxE. Pore architecture and ion sites in acid-sensing ion channels and P2X receptors.Nature460, 599–605 (2009).
   PubMed Web of Science ®Google Scholar
• Reyhan D , LeuwerM, de la Roche J et al. Modulation of glycine receptor function by the synthetic cannabinoid HU210. Pharmacology83(5), 270–274 (2009).
   PubMed Web of Science ®Google Scholar
• Holzer P . Acid sensor ion channels and receptors.Handb. Exp. Pharmacol.194, 283–332 (2009).
   Google Scholar
• Lindahl O . Pain: a chemical explanation.Acta Rheumatol. Scand.8, 161–169 (1962).
   PubMedGoogle Scholar
• Reeh PW , SteenKH. Tissue acidosis in nociception and pain.Prog. Brain Res.113, 143–151 (1996).
   PubMed Web of Science ®Google Scholar
• Voilley N , De Weille J, Mamet J, Lazdunski M. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J. Neurosci.21(20), 8026–8033 (2001).
   PubMed Web of Science ®Google Scholar
• Mamet J , BaronA, LazdunskyM, VoilleyN. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels.J.Neurosci.22(24), 10662–10670 (2002).
   PubMed Web of Science ®Google Scholar
• Ferreira J , SantosAR, CalixtoJB. Antinociception produced by systemic, spinal and supraspinal administration of amiloride in mice.Life Sci.65(10), 1059–1066 (1999).
   PubMed Web of Science ®Google Scholar
• Xu TL , DuanB. Calcium-permeable acid-sensing ion channel in nociceptive plasticity: a new target for pain control.Prog. Neurobiol.87, 171–180 (2009).
   PubMed Web of Science ®Google Scholar
• Poirot O , BertaT, DecosterdI, KellenbergerS. Distinct ASIC currents are expressed in rat putative nociceptors and are modulated by nerve injury.J. Physiol.576(1), 215–234 (2006).
   PubMed Web of Science ®Google Scholar
• Mazzuca M ., Heurteaux C, Alloui A et al. A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat. Neurosci.10(8), 943–945 (2007).
   PubMed Web of Science ®Google Scholar
• Munro G , AhringPK, MirzaNR. Developing analgesic by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol. Sci.30(9), 453–459 (2009).
   PubMed Web of Science ®Google Scholar
• Enna SJ , McCarsonKE. The role of GABA in the mediation and perception of pain.Adv. Pharmacol.54, 1–27 (2006).
   PubMedGoogle Scholar
• Sieghart W . Structure, pharmacology, and function of GABAA receptor subtypes. Adv. Pharmacol.54, 231–263 (2006).
   PubMedGoogle Scholar
• Carlton SM , ZhouS, CoggeshallRE. Peripheral GABAA receptors: evidence for peripheral primary afferent depolarization. Neuroscience93(2), 713–722 (1999).
   PubMed Web of Science ®Google Scholar
• Bohlhalter S , WeinmannO, MohlerH, Frirschy J-M. Laminar compartmentalization of GABAA-receptor subtypes in the spinal cord: an immunohistochemical study. J. Neurosci.16(1), 283–297 (1996).
   PubMed Web of Science ®Google Scholar
• Melzack R , WallP .D. Pain mechanism: a new theory. Science150, 971–979 (1965).
   PubMed Web of Science ®Google Scholar
• Kaneko M , HammondDL. Role of spinal γ-aminobutyric acid A receptors in formalin-induced nociception in the rat.J.Pharmacol. Exp Ther.282(2), 928–938 (1997).
   PubMed Web of Science ®Google Scholar
• Malan TP , MataHP, PorrecaF. Spinal GABAA and GABAB receptor pharmacology in a rat model of neuropathic pain. Anesthesiology96, 1161–1167 (2002).
   PubMed Web of Science ®Google Scholar
• Rode F , JensenDG, Blackburn-MunroG, BjerrumOJ. Centrally-mediated antinociceptive actions of GABAA receptor agonists in the rat spared nerve injury model of neuropathic pain. Eur. J. Pharmacol.516, 131–138 (2005).
   PubMed Web of Science ®Google Scholar
• Naik AK , PathirathnaS, Jevtovic-TodorovicV. GABAA receptor modulation in dorsal root ganglia in vivo affects chronic pain after nerve injury. Neuroscience154, 1539–1553 (2008).
   PubMed Web of Science ®Google Scholar
• Hwang JH , YakshTL. The effect of spinal GABA receptor agonist on tactile allodynia in a surgically-induced neuropathic pain model in the rat.Pain70(1), 15–22 (1997).
   PubMed Web of Science ®Google Scholar
• Loomis CW , KhandwalaH, OsmondG, HefferanMP. Coadministration of intrathecal strychnine and bicuculline effects synergistic allodynia in the rat: an isobolographic analysis.J. Pharmacol. Exp. Ther.296(3), 756–761 (2001).
   PubMed Web of Science ®Google Scholar
• Polgar E , HughesDI, RiddelJS, MaxwellDJ, PuskarZ, ToddAJ. Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain.Pain104(1–2), 229–239 (2003).
   PubMed Web of Science ®Google Scholar
• Drew GM , SiddalPJ, DugganAW. Mechanical allodynia following contusion injury of the rat spinal cord is associated with loss of GABAergic inhibition in the dorsal horn.Pain109, 379–388 (2004).
   PubMed Web of Science ®Google Scholar
• Ibuki T , HamaAT, WangXT, PappasGD, SagenJ. Loss of GABA-immunoreactivity in the spinal dorsal horn of rats with peripheral nerve injury and promotion of recovery by adrenal medullary grafts.Neuroscience76, 845–858 (1997).
   PubMed Web of Science ®Google Scholar
• Miletic G , DraganicP, PankratzMT, MileticV. Muscimol prevents long-lasting potentiation of dorsal horn field potential in rats with chronic constriction injury exhibiting decreased levels of the GABA transporter GAT-1.Pain105, 347–353 (2003).
   PubMed Web of Science ®Google Scholar
• Obata K , YamanakaH, FukuokaTet al. Contribution of injured and uninjured dorsal root ganglion neurons to pain behavior and the changes in gene expression following chronic constriction injury of the sciatic nerve in rats. Pain 101, 65–77 (2003).
   PubMed Web of Science ®Google Scholar
• Rudolph U , MohlerH. Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu. Rev. Pharmacol. Toxicol.44, 475–498 (2004).
   PubMed Web of Science ®Google Scholar
• Knabl J , WitschiR, HoslKet al. Reversal of pathological pain through specific GABAA receptor subtypes. Nature 451, 330–335 (2008).
   PubMed Web of Science ®Google Scholar
• Rudolph U , CrestaniF, BenkeDet al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid (A) receptor subtypes. Nature 401(6755), 796–800 (1999).
   PubMed Web of Science ®Google Scholar
• McKernan RM , RosahlTW, ReynoldsDSet al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor a 1 subtype. Nat. Neurosci. 3(6), 587–692 (2000).
   PubMed Web of Science ®Google Scholar
• Mirza NR , LarsenJS, MathiasenCet al. NS11394 [3´-[5-(1-hydroxy-1-methyl-ethil)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy. J. Pharmacol. Exp. Ther. 327(3), 954–968 (2008).
   PubMed Web of Science ®Google Scholar
• Munro G , Lopez-GarciaJA, Rivera-ArconadaIet al. Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3‘-[5-(1-hydroxy-1-methyl-ethil)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil and gaboxadol in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 327, 969–981 (2008).
   PubMed Web of Science ®Google Scholar
• Knabl J , WitschiR, HoslKet al. Reversal of pathological pain through specific GABAA receptor subtypes. Nature 451, 330–335 (2008).
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU , MohlerH, Di Lio A. GABAergic analgesia: new insights from mutant mice and subtype-selective agonists. Trends Pharmacol. Sci.30(8), 397–402 (2009).
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU , WitschiR, HolsK. Subtype-selective GABAA receptor mimetics-novel antihyperalgesic agents? J. Mol. Med.87, 465–469 (2009).
   PubMed Web of Science ®Google Scholar
• Lynch JW . Native glycine receptor subtypes and their physiological role.Neuropharmacol.56, 303–309 (2009).
   PubMed Web of Science ®Google Scholar
• Lynch JW . Molecular structure and function of the glycine receptor chloride channel.Physiol. Rev.84, 1051–1095 (2004).
   PubMed Web of Science ®Google Scholar
• Webb TI , LynchJW. Molecular pharmacology of the glycine receptor chloride channels.Curr. Pharm Des.13, 2350–2367 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch JW , CallisterRJ. Glycine receptors: a new therapeutic target in pain pathways.Curr. Opin. Investig. Drugs.7(1): 48–53 (2006).
   PubMedGoogle Scholar
• Harvey RJ , DepnerUB, WassleHet al. GlyR α3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 304(5672), 884–887 (2004).
   PubMed Web of Science ®Google Scholar
• Ahmadi S , LipprossS, NeuhuberWL, ZeilhoferHU. PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons.Nat. Neurosci.5(1), 34–40 (2002).
   PubMed Web of Science ®Google Scholar
• Racz I , SchutzB, Abo-SalemOM, ZimmerA. Visceral, inflammatory and neuropathic pain in glycine receptor α 3-deficient mice.Neuroreport16(18), 2025–2028 (2005).
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU . The glycinergic control of spinal pain processing.Cell. Mol. Life Sci.62, 1–9 (2005).
   PubMed Web of Science ®Google Scholar
• Pellicer F . Lopez-Avila A. Coffeen U. Ortega-Legaspi JM, Del Angel R. Taurine in the anterior cingulated cortex diminishes neuropathic nociception: a possible interaction with the glycine A receptor.Pain11, 444–451 (2007).
   Web of Science ®Google Scholar
• Ahrens J , ReyhanD, LeuwerMet al. The nonpsychotropic cannabinoid cannabidiol modelates and directly activates α-1 and α-1-β glycine receptor function. Pharmacology 83(4), 217–222 (2009).
   PubMed Web of Science ®Google Scholar
• Muth-Sebach U , HermannsH, StegmannJUet al. Antinociceptive effects of systemic lidocaine: involvement of the spinal glycinergic system. Eur. J. Pharmacol. 613(1–3), 68–73 (2009).
   PubMed Web of Science ®Google Scholar
• Dekermendjian K , WennaN, AneirosE, BernströmJ, NymanE. Discovery of novel positive allosteric modulators for the inhibitor glycine receptor.Presented at: 38th Annual Meeting for the Society for Neuroscience 729.3, Washingon, DC, USA, 15–19 November 2008.
   Google Scholar
• Derbach V , SurprenantA, NorthRA. 5-HT3 receptors are membrane ion channels.Nature339, 706–709 (1989).
   PubMed Web of Science ®Google Scholar
• Hoyer D , ClarkeDE, FozardJRet al. International union of pharmacology classification of receptors for 5- hydroxytryptamine (serotonin). Pharmacol. Rev. 46, 157–203 (1994).
   PubMed Web of Science ®Google Scholar
• Herrmann S , StieberJ, LudwigA. Pathophysiology of HCN channels.Pflugers Arch.454(4), 517–522 (2007).
   PubMed Web of Science ®Google Scholar
• Barnes NM , HalesTG, LummisS, PetersJA. The 5-HT3 receptor – the relationship between structure and function.Neuropharmacol.56, 273–284 (2009).
   PubMed Web of Science ®Google Scholar
• Miquel MC , EmeritMB, NosjeanAet al. Differential subcellular localization of the 5-HT3-A receptor subunit in the rat central nervous system. Eur. J. Neurosci. 15, 449–457 (2002).
   PubMed Web of Science ®Google Scholar
• Pierce PA , XieGX, LevineJD, PeroutkaSJ. 5-Hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: a polymerase chain reaction study.Neuroscience70, 553–559 (1996).
   PubMed Web of Science ®Google Scholar
• Richardson BP , EngelG, DonatschP, StadlerPA. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs.Nature316, 126–131 (1985).
   PubMed Web of Science ®Google Scholar
• Sufka KJ , SchomburgFM, GiordanoJ. Receptor mediation of 5-HT-induced inflammation and nociception in rats.Pharmacol. Biochem. Behav.41, 53–56 (1992).
   PubMed Web of Science ®Google Scholar
• Zeitz KP , GuyN, MalmbergABet al. The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J. Neurosci. 22, 1010–1019 (2002).
   PubMed Web of Science ®Google Scholar
• Espejo EF , GilE. Antagonism of peripheral 5-HT4 receptors reduces visceral and cutaneous pain in mice, and induces visceral analgesia after simultaneous inactivation of 5- HT3 receptors.Brain Res.788, 20–24 (1998).
   PubMed Web of Science ®Google Scholar
• Giordano J , DycheJ. Differential analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse.Neuropharmacol.28, 423–427 (1989).
   PubMed Web of Science ®Google Scholar
• Giordano J , RogersLV. Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats.Eur. J. Pharmacol.170, 83–86 (1989).
   PubMed Web of Science ®Google Scholar
• Eschalier A , KayserV, GuilbaudG. Influence of a specific 5-HT3 antagonist on carrageenan-induced hyperalgesia in rats.Pain36, 249–255 (1989).
   PubMed Web of Science ®Google Scholar
• Chen Y , OatwayMA, WeaverLC. Blockade of the 5-HT3 receptor for days causes sustained relief from mechanical allodynia following spinal cord injury. J. Neurosci. Res.87, 418–424 (2009).
   PubMed Web of Science ®Google Scholar
• Fozard JR . Neuronal 5-HT receptors in the periphery.Neuropharmacol.23, 1473–1486 (1984).
   PubMed Web of Science ®Google Scholar
• Giordano J , DaleoC, SacksSM. Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans.Eur. J. Pharmacol.354, R13–14 (1998).
   PubMed Web of Science ®Google Scholar
• McCleane GJ , SuzukiR, DickensonAH. Does a single intravenous injection of the 5HT3 receptor antagonist ondansetron have an analgesic effect in neuropathic pain? A double-blinded, placebo-controlled cross-over study. Anesth. Analg.97, 1474–1478 (2003).
   PubMed Web of Science ®Google Scholar
• Ye JH , MuiWC, RenJet al. Ondansetron exhibits the properties of a local anesthetic. Anesth. Analg. 85, 1116–1121 (1997).
   PubMed Web of Science ®Google Scholar
• Ambesh SP , DubeyPK, SinhaPK. Ondansetron pretreatment to alleviate pain on propofol injection: a randomized, controlled, double-blinded study.Anesth. Analg.98, 197–199 (1999).
   Google Scholar
• Fearber L , DrechslerS, LadenburgerS, GschaidmeierH, FischerW. The neuronal 5-HT3 receptor network after 20 years of research – evolving concepts in management of pain and inflammation. Eur. J. Pharm.560, 1–8 (2007).
   PubMed Web of Science ®Google Scholar
• Suzuki T , YongHL, TakashiM. The antiallodynic and antihyperalgesic effects of Neurotropin® in mice with spinal nerve ligation. Anesth. Analg.101, 793–799 (2005).
   PubMed Web of Science ®Google Scholar
• Gotti C , ClementiF. Neuronal nicotinic receptors: from structure to pathology.Prog. Neurobiol.74(6), 363–396 (2004).
   PubMed Web of Science ®Google Scholar
• Gerzanich V , WangF, KuryatovA, LindstromJ. α5-subunit alters desensitization, pharmacology, Ca2+ permeability and Ca2+ modulation of human neuronal α3 nicotinic receptors. J. Pharmacol. Exp. Ther.286(1), 311–320 (1998).
   PubMed Web of Science ®Google Scholar
• Nelson ME , LindstromJ. Single channel properties of human α3 AChRs: impact of β2, β4 and α5 subunits.J. Physiol.516(3), 657–678 (1999).
   PubMed Web of Science ®Google Scholar
• Haberberger RV , BernardiniN, KressM, HartmannP, LipsKS, KummerW. Nicotinic acetylcholine receptor subtypes in nociceptive dorsal root ganglion neurons of the adult rat.Auton. Neurosci.113, 32–42 (2004).
   PubMed Web of Science ®Google Scholar
• Khan I , OsakaH, StanislausS. Nicotinic acetylcholine receptors distribution in relation to spinal neurotransmission pathways.J. Comp. Neurol.467(1), 44–59 (2003).
   PubMed Web of Science ®Google Scholar
• Aceto MD , BagleyRS, DeweyWL, FuTC, MartinBR. The spinal cord as a major site for the antinociceptive action of nicotine in the rat.Neuropharmacol.25, 1031–1036 (1986).
   PubMed Web of Science ®Google Scholar
• Badio B , DalyJW. Epibatidine, a potent analgetic and nicotinic agonist.Mol. Pharmacol.45, 563–569 (1994).
   PubMed Web of Science ®Google Scholar
• Marubio LM , Arroyo-JimenezMM, Cordero-ErausquinMet al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398, 805–810 (1999).
   PubMed Web of Science ®Google Scholar
• Bitner RS , NikkelAL, CurzonPet al. Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Res. 871, 66–74 (2000).
   PubMed Web of Science ®Google Scholar
• Damaj MI , FonckC, MarksMJet al. Genetic approaches identify differential roles for α4β2 nicotinic receptors in acute models of antinociception in mice. J. Pharmacol. Exp. Ther. 321, 1161–1169 (2007).
   PubMed Web of Science ®Google Scholar
• Wonnacott S , SoliakovL, WilkieG, RedfernP, MarshallD. Presynaptic nicotinic acetylcholine receptors in the brain.Drug Dev. Res.38, 149–159 (1996).
   Web of Science ®Google Scholar
• Rueter LE , KohlassKL, CurzonP, SurowyCS, MeyerMD. Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain.Pain103(3), 269–276 (2003).
   PubMed Web of Science ®Google Scholar
• Kesingland AC , GentryCT, PanesarMSet al. Analgesic prolfile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain. Pain 86(1–2), 113–118 (2000).
   PubMed Web of Science ®Google Scholar
• Bannon AW , DeckerMW, KimDJ, CampbellJE, ArnericSP. ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain.Brain Res.801(1–2), 158–163 (1998).
   PubMed Web of Science ®Google Scholar
• Jordan KG , HauserTA, FedorovN, TrainaVM, BencherifM. TC-6499: an orally effective and selective α-4-β-2 neuronal nicotinic receptor agonist with anti-allodynic activity. 37th Annual Meeting of the Society for Neuroscience abstr. 39.7, San Diego, CA, USA, 3–7 November 2007.
   Google Scholar
• Arneric SP , HolladayM, WilliamsM. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research.Biochemical Pharmacol.74, 1092–1101 (2007).
   PubMed Web of Science ®Google Scholar
• Taly A , CirringerPJ, GuedinD, LestageP, ChangeuxJP. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.Nat. Rev. Drug Discov.8, 733–750 (2009).
   PubMed Web of Science ®Google Scholar
• Blackburn-Munro G , Dalby-BrownW, MirzaN R, Mikkelsen JD, Blackburn-Munro RE. Retigabine: chemical synthesis to clinical application. CNS Drug Rev.11(1), 1–20 (2005).
   PubMedGoogle Scholar
• Cattabeni F . Ralfinamide.IDrugs7(10), 935–939 (2004).
   PubMedGoogle Scholar
• Colombo E , CuratoloL, CacciaC, FaravelliLet al. Ralfinamide acts through NMDA receptor complex: a central role for chronic pain treatment. Eur.J. Pain , 11(1), 152–153 (2007).
   Google Scholar
• Barbieri M , BregolaG, BuzziAet al. Mechanisms of action of CHF3381 in the forebrain. Br. J. Pharmacol. 139, 1333–1341 (2003).
   PubMed Web of Science ®Google Scholar
• Simpson DM , BrownSJ, TobiasJ. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.Neurology70, 2305–2313 (2008).
   PubMed Web of Science ®Google Scholar
• Simpson DM , EstanislaoL, BrownSJ. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy.Pain Symptom. Manag.35, 299–306 (2008).
   PubMed Web of Science ®Google Scholar
• Rami HK , ThompsonM, StempGet al. Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg. Med. Chem. Lett. 16(12) 3287–3291 (2006).
   PubMed Web of Science ®Google Scholar
• Swanson DM , DubinAE, ShahCet al. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem. 48(6), 1857–1872 (2005).
   PubMed Web of Science ®Google Scholar
• Pomonis JD , HarrisonJE, MarkL, BristolDR, ValenzanoKJ, WalkerK. N-4-tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo vharacterization in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther.306, 387–393 (2003).
   PubMed Web of Science ®Google Scholar
• Culshaw AJ , BevanS, ChristiansenMet al. Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain. J. Med. Chem. 49(2), 471–474 (2006).
   PubMed Web of Science ®Google Scholar
• Walpole CSJ , BevanS, BovermannGet al. The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J. Med. Chem. 37(13), 1942–1954 (1994).
   PubMed Web of Science ®Google Scholar
• Walker KM , UrbanL, MedhurstSJet al. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J. Pharm. Exp. Ther. 304, 56–62 (2003).
   PubMed Web of Science ®Google Scholar
• Gauvin DM , MikusaJ, BakerSet al. A-967079, a potent and selective TRPA1 antagonist, is efficacious in rat preclinical pain models. Presented at: 39th Annual Meeting of the Society for Neuroscience. Chicago, IL, USA, 17–21 October 2009 (Abstract 761.3).
   Google Scholar
• Watanabe S , OhmiM, InoueT, NonomuraC, FujiiuchiA. Identification of novel TRPM8 channel antagonists. Presented at: 39th Annual Meeting of the Society for Neuroscience. Chicago, IL, USA, 17–21 October 2009 (Abstract 73.7).
   Google Scholar
• Anand R , RossettiSM, MarchettiniPet al. Efficacy and safety of ralfinamide in a 8-week, randomised, double-blind, placebo controlled, international trial in patients with neuropathic pain. Ralfinamide 001 study group. Presented at: 60th Annual Meeting of the American Academy of Neurology. 11–14 April 2008 (Abstract P03,179).
   Google Scholar
• Zhang S -H, Blech-Hermoni Y, Seltzer, Z, Faravelli L et al. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain39(2), 293–305 (2008).
   Google Scholar
• Stummann TC , SalvatiP, FarielloRG, and Faravelli L. The anti-nociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ currents in dorsal root ganglion neurons. Eur.J.Pharmacol.510(3), 197–208 (2005).
   PubMed Web of Science ®Google Scholar
• Yamane H , de Groat WC, Sculptoreanu A. Effects of ralfinamide, a Na+ channel blocker, on firing properties of nociceptive dorsal root ganglion neurons of adult rats. Exper. Neurol.208, 63–72 (2007).
   PubMed Web of Science ®Google Scholar
• Brochu RM , DickIE, TarpleyJWet al. Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats. Mol. Pharmacol. 69(3), 823–832 (2006).
   PubMed Web of Science ®Google Scholar
• Shao PP , OkD, FisherMHet al. Novel cyclopentane dicarboxamide sodium channel blocker, as potential treatment for chronic pain. Bioorg. Med. Che. Lett. 15(7), 1901–1907 (2005).
   PubMed Web of Science ®Google Scholar
• Jarvis MF , HonoreP, Shieh C-C et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl Acad. Sci. USA104(20), 8520–8525 (2007).
   PubMed Web of Science ®Google Scholar
• Kort ME , DrizinI, GreggRJet al. Discovery and biological evaluation of 5-aryl-2-furfuramides. Potent and selective blockers of Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J. Med. Chem. 51, 407–416 (2008).
   PubMed Web of Science ®Google Scholar
• Hoyt SB , LondonC, OkDet al. Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. Bioorg. Med. Chem. Lett. 17(22), 6172–6177 (2007).
   PubMed Web of Science ®Google Scholar
• Williams BS , FelixJP, PriestBTet al. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry 46(50), 14693–14703 (2007).
   PubMed Web of Science ®Google Scholar
• McGowan E , HoytSB, LiXet al. A peripherally acting Nav1.7 sodium channel blocker reverses hyperalgesia and allodynia on rat models of inflammatory and neuropathic pain. Anesth. Analg. 109, 951–958 (2009).
   PubMed Web of Science ®Google Scholar
• Zamponi GW , Feng Z-P, Zhang L et al. Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg. Med. Chem. Lett.19, 6467–6472 (2009).
   PubMed Web of Science ®Google Scholar
• Knutsen LJS , HobbsCJ, EarnshawCGet al. Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg. Med. Chem. Lett. 17(3), 662–667 (2007).
   PubMed Web of Science ®Google Scholar
• Yamamoto T , NiwaS, OhnoSet al. The structure activity relationship study on the water-soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels. 20th International Symposium on Medicinal Chemistry abstr. P150, 31 August 2008.
   Google Scholar
• Saito Y , KiriharaY, HashimotoTet al. Spinal antinociceptive effects of a new calcium channel blocker, AGS1164, in rats. 33rd Annual Meeting of the Society for Neuroscience. New Orleans, LA, 8–12 November 2003.
   Google Scholar
• Koganei H , FujitaS, IwayamaSet al. Analgesic effects of a novel compound which posseses N-type calcium channel blocking activity. 32rd Annual Meeting of the Society for Neuroscience abs. 656.2, Orlando, FL, 2–7 November 2002.
   Google Scholar
• Yang Z -Q, Barrow JC, Shipe WD et al. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J. Med. Chem.51(20), 6471–6477 (2009).
   Web of Science ®Google Scholar
• Goodchild CS , NelsonJ, CookeI, AshbyM, JacksonK. Combination therapy with flupirtine and opioid: open-label case series in the treatment of neuropathic pain associated with cancer.Pain Med.9(7), 939–949 (2008).
   PubMed Web of Science ®Google Scholar
• Wickenden AD , McNaughton-SmithG, RoeloffsR, LondonB, ClarkS. ICA-27243: a novel, potent, and selective KCNQ2/Q3 potassium channel activator. Presented at: 35th Annual Meeting of the Society for Neuroscience Washington, DC, USA, 12–16 November 2005 (Abstract 153.13).
   Google Scholar
• Roeloffs R , HarrisonW, MahoneyJH, LeachC, RobinetteL. In vivo profile of a KCNQ2/3 selective versus a pan-KCNQ activator in rodent models of pain. Presented at: 38th Annual Meeting of the Society for Neuroscience Washington, DC, USA 15–18 November 2008 (Abstract 631.4).
   Google Scholar
• Wickenden AD , KrajewskiJL, LondonBet al. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator. Mol. Pharmacol. 73(3), 977–986 (2008).
   PubMed Web of Science ®Google Scholar
• Wu YJ , HeH, Sun L-Q et al. Synthesis and structure–activity relationship of acrylamides as KCNQ2 potassium channel openers. J. Med. Chem.47(11), 2887–2896 (2004).
   PubMed Web of Science ®Google Scholar
• Boden PR , GentryC, LhullerL, AzizO. Novel compounds which disrupt Kv1.1/Kv-β-1-subunit interactions are antianalgesic in vivo. Presented at: 37th Annual Meeting of the Society for Neuroscience San Diego, CA, 3–7 November 2007 (Abstract 469.30).
   Google Scholar
• Mangat M , SchmudermaierM, DubéGR, SchmudermaierB, GervaisF, GustorffB. The effects of PPC-5650, an ASIC1a antagonist on hyperalgesia in a human inflammatory pain model. Presented at: The 11th International Conference on the Mechanisms and Treatment of Neuropathic Pain 6–8 November 2008.
   Google Scholar
• Simard B , PaquetM, ElagozAet al. PPC-5692, a novel and selective ASIC1a antagonist, exerts analgesic effects across multiple animal pain models. Presented at: 38th Annual Meeting for the Society for Neuroscience Washington, DC, USA, 15–19 November 2008 (Abstract 857.14).
   Google Scholar
• Bordet T , BuissonB, MichaudMet al. Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. J. Pharmacol. Exp. Therap. 326(2), 623–632 (2008).
   PubMed Web of Science ®Google Scholar
• Walters R , BradfordAPJ, FischerJet al. Early clinical experience with the novel NMDA receptor antagonist CNS 5161. Br J Clin Pharmacol. 53(3), 305–311 (2002).
   PubMed Web of Science ®Google Scholar
• Hu L -Y, Guo J, Magar SS et al. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N-3-substituted phenyl)-N-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers. J. Med. Chem.40, 4281–4289 (1997).
   PubMed Web of Science ®Google Scholar
• Tarral A , DostertP, GuillevicYet al. Pharmacokinetics and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects. J. Clin. Pharm. 43(8), 901–911 (2003).
   PubMed Web of Science ®Google Scholar
• Villetti G , BregolaG, BassaniFet al. Preclinical evaluation of CHF3381 as a novel antiepileptic agent. Neuropharmacol. 40, 866 (2001).
   PubMed Web of Science ®Google Scholar
• Zucchini S , BuzziA, BergamaschiMet al. Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist. Neuroreport 13, 2071–2074 (2002).
   PubMed Web of Science ®Google Scholar
• Rammes G . Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications.Exp. Rev. Clin. Pharmacol.2(3), 231–238 (2009).
   PubMedGoogle Scholar
• Chen SR , SamoriskiG, PanHL. Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain.Neuropharmacol.57(2), 121–126 (2009).
   PubMed Web of Science ®Google Scholar
• Malyshkin AA , MedvedevIO, DanyszWet al. Anti-allodynic interactions between NMDA receptor channel blockers and morphine or clonidine in neuropathic rats. Eur. J. Pharmacol. 519(1–2), 80–85 (2005).
   PubMed Web of Science ®Google Scholar
• Klein T , MagerlW, HanschmannAet al. Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia. Eur.J.Pain (Amsterdam, Netherlands) 12(1), 17–29 (2007).
   Google Scholar
• Erichsen HK , Blackburn-MunroG. Pharmacological characterisation of the spared nerve injury model of neuropathic pain.Pain98(1–2), 151–161 (2002).
   PubMed Web of Science ®Google Scholar
• Blackburn-Munro G , BomholtS, ErichsenHKet al. Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain. Neuropharmacol. 47(3), 351–362 (2004).
   PubMed Web of Science ®Google Scholar
• Gormsen L , FinnerupNB, AlmqvistPMet al. The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth. Analg. 108(4), 1311–1319 (2009).
   PubMed Web of Science ®Google Scholar
• Kasper C , PickeringDS, MirzaOet al. The structure of a mixed GluR2 ligand-binding core dimer in complex with (S)-glutamate and the antagonist (S)-NS1209. J. Mol. Biol. 357(4), 1184–1201 (2006).
   PubMed Web of Science ®Google Scholar
• Pinza M , FarinaC, CerriAet al. Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers. J. Med. Chem. 36(26), 4214–4220 (1993).
   PubMed Web of Science ®Google Scholar
• Farina C , GagliardiS, GhelardiniCet al. Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain. Bioorg. Med. Chem. 16(6), 3224–3232 (2008).
   PubMed Web of Science ®Google Scholar
• Bonanno G , MisianoP, BonifacinoTet al. Effects of BND-11624 at ionotropic and metabotropic glutamatergic receptors regulating neurotransmitter release in the rat CNS. Annual Meeting of the Society for Neuroscience. Atlanta, US, 17 November 2008 (Abstract 368.2/JJ27).
   Google Scholar
• Farkas S , HorvathC, NagyJet al. RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. 33rd Annual Meeting of the Society for Neuroscience. New Orleans, LA, USA, 8–12 November 2009.
   Google Scholar
• Barta-Szalai G , BorzaI, BozoEet al. Oxamides as novel NR2B selective NMDA receptor antagonists. Bioorg. Med.Chem. Lett. 14(15), 3953–3956 (2004).
   PubMed Web of Science ®Google Scholar
• Palecek J , NeugebauerV, CarltonsM, IyengarS. Willis WD. The effect of a kainate GluR5 receptor antagonist on responses of spinothalamic tract neurons in a model of peripheral neuropathy in primates.Pain111(1–2), 151–161 (2004).
   PubMed Web of Science ®Google Scholar
• Baudy RB , ButeraJA, Abou-GharbiaMAet al. Prodrugs of perzinfotel with improved oral bioavailability. J. Med. Chem. 52(3), 771–778 (2009).
   PubMed Web of Science ®Google Scholar
• Perez-Medrano A , Donnelly-RobertsDL, HonorePet al. Discovery and biological evaluation of novel cyanoguanidine P2X7 antagonists with analgesic activity in a rat model of neuropathic pain. J. Med. Chem. 52, 3366–3376 (2009).
   PubMed Web of Science ®Google Scholar
• Nelson DW , GreggRJ, KortMEet al. Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J. Med. Chem. 49, 3659–3666 (2006).
   PubMed Web of Science ®Google Scholar
• Jahangir A , AlamM, CarterDSet al. Identification and SAR of novel diaminopyrimidines. Part 2: the discovery of RO-51, a potent and selective, dual P2X3/P2X2/3 antagonist for the treatment of pain. Bioorg. Med. Chem. Lett. 19(6), 1632–1635 (2009).
   PubMed Web of Science ®Google Scholar
• Crean CS , YerxaBR, BednarskiKet al. Analgesic effects of INS48506, a P2X(3) receptor antagonist, in models of acute, inflammatory and neuropathic pain. 33rd Annual Meeting of the Society for Neuroscience. New Orleans, LA, USA, 8–12 November 2003.
   Google Scholar
• Hsu DR , Wei Z-L, O‘Mohony DJR et al. Novel antagonists of P2X3 and P2X2/3 purinergic receptors. 37th Annual Meeting of the Society for Neuroscience Abstr. 820.13, San Diego, CA, USA, 3–7 November 2007.
   Google Scholar
• Rueter LE , CurzonP, KohlhaasK, GauvinD, HonoreP. ABT-894, a neuronal nicotinic receptor agonist, with an improved therapeutic window in preclinical models of neuropathic pain vs. gastrointestinal and CNS side effects. 38th Annual Meeting for the Society for Neuroscience. Washington, DC, USA, 15–19 November 2008 (Abstract 856.20).
   Google Scholar
• Lippiello PM , GattoGJ, JordanKG, BencherifM. Novel neuronal nicotinic receptor selective compounds for the treatment of acute, chronic and neurpathic pain.Eur. Neuropsychopharmacol.17 (4), 252 (2007).
   Google Scholar
• Holtman J , Johnson-HardyJ, CrooksP, ChakrabortyU, WalaE. Novel opioid-nicotinic combination drug therapy for pain. 28th Annual Scientific Meeting of the American Pain Society 29 Abstract. 216, 7 May 2009.
   Google Scholar
• Rueter LE , KohlhaasKL, CurzonP, SurowyCS, MeyerMD. Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain.Pain103(3), 269–276 (2003).
   PubMed Web of Science ®Google Scholar
• Dunlop J , VasilyevD, LuP, CummonsT, BowlbyMR. Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and pain.Curr. Pharm. Des.15, 1767–1772 (2009).
   PubMed Web of Science ®Google Scholar
• Jiang YQ , SunQ, TuHY, WanY. Characteristic of HCN channels and their participation in neuropathic pain.Neurochem. Res.33, 1979–1989 (2008).
   PubMed Web of Science ®Google Scholar
• Maher MP , Wu N-T, Guo H-Q,Dubin AE, Chaplan SR, Wickenden AD: HCN channels as targets for drug discovery. Comb. Chem.High Through. Screen.12(1), 64–72 (2009).
   PubMed Web of Science ®Google Scholar

Patents

• Les Laboratoire Servier: WO2009066041
   Google Scholar
• Glenmark Pharmaceuticals: WO 2007042906
   Google Scholar
• Sanofi-Aventis: WO 2007010144
   Google Scholar
• Mochida: WO2008091021
   Google Scholar
• Mochida: WO2007010383
   Google Scholar
• Ionix Pharmaceuticals Ltd.: WO2005000309
   Google Scholar
• Neuromed: WO2008141446
   Google Scholar
• Merck&Co.: WO2007084394
   Google Scholar
• Wyeth: WO2008073936
   Google Scholar
• Wyeth: WO2008073934
   Google Scholar
• Merck&Co.: WO2007120729
   Google Scholar
• Merck&Co.: WO2009045382
   Google Scholar
• Merck&Co.: WO2009054983
   Google Scholar
• Merck&Co.: WO2009054984
   Google Scholar
• Merck&Co.: WO2009009015
   Google Scholar
• Merck&Co.: WO2009045386
   Google Scholar
• Merck&Co./Neuromed: WO2009045382
   Google Scholar
• Merck&Co.: WO2008133867
   Google Scholar
• Lectus Therapeutics: WO2009071947
   Google Scholar
• Painceptor Pharma Corp.: WO 2007059608
   Google Scholar
• Evotec Neurosciences GmbH: WO2009118187
   Google Scholar
• F. Hoffman La Roche AG: WO2003097637
   Google Scholar

Websites

• Forecast insight: neuropathic pain (DMHC2567–12/2009) www.datamonitor.com
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety of ralfinamide in patients with chronic neuropathic low back pain http://clinicaltrials.gov/ct2/show/NCT01019824
   Google Scholar
• The Medical News. Leconotide, an investigative calcium channel blocker, shows potential as pain treatment. 29 January 2009 www.news-medical.net/news/2009/01/29/45329.aspx
   Google Scholar
• Valeant Pharmaceuticals announces preliminary results from its Phase Iia retigabine study for the treatment of Post-herpetic Neuralgia www.valeant.com
   Google Scholar
• Icagen initiating Phase I clinical development program for ICA-69673, a novel drug candidate for epilepsy www.icagen.com
   Google Scholar
• Icagen presents results of Phase I program of ICA-105665 (Part A)www.icagen.com
   Google Scholar
• American College of Rheumatology. Results of a Phase II clinical trial of a novel P2X7 receptor antagonists, AZD9056, in patients with active rheumatoid arthritis (CREATE Study) http://acr.confex.com/acr/2007/webprogram/Paper8110.html
   Google Scholar
• ClinicalTrials.gov. First time in human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and the effect of food of single assending doses of GSK1482160 http://clinicaltrials.gov/ct2/show/record/NCT00849134
   Google Scholar
• Evotec AG. Evotec announces the successful completion of the first Phase I study with EVT 401, an oral P2X7 receptor antagonist – very good safety profile and confirmed ‘on target activity’ www.evotec.com
   Google Scholar
• ClinicalTrials.gov. NCT00006289, Neurotropin to treat chronic neuropathic pain http://clinicaltrials.gov
   Google Scholar
• Clinical Trials www.clinicaltrial.gov/ct2/results?term=NGX-4010
   Google Scholar
• Glenmark Pharmaceuticals S.A. Glenmark’s lead candidate pain, GRC 6211, to enter Phase II trials in Europe www.glenmarkpharma.com
   Google Scholar
• Glenmark Pharmaceuticals Ltd. Further clinical trials in ostheosrthritis pain suspended for GRC 6211. October 24, 2008 www.glenmarkpharma.com
   Google Scholar
• Sanofi-Aventis (slide 62) http://en.sanofi-aventis.com/binaries/FY2008_EN_V5_tcm28–23943.pdf
   Google Scholar
• Mochida Pharmaceutical Co. Ltd. Mochida Announces Conclusion of License Agreement with Wyeth www.mochida.co.jp/english/news/2008/0109.html
   Google Scholar
• Vernalis. Neuropathic Pain: V3381 www.vernalis.com/ver/rdc2/pipeline/v3381/
   Google Scholar
• CNSBio. Research and development pipeline www.cnsbio.com/index.php?option=com_content&view=category&layout=blog&id=4&Itemid=7
   Google Scholar
• Monash Institute Annual Report 2008 www.monashinstitute.org/assets/media/annualreport/report-2008.pdf
   Google Scholar
• Lectus Therapeutics announces preclinical ‘Proof-of-Concept’ data www.lectustherapeutics.com
   Google Scholar
• ClinicalTrials.gov. NCT00661063, Diabetic neuropathy topical treatment http://clinicaltrials.gov
   Google Scholar
• ClinicalTrials.gov. NCT00471445 Topical amitriptyline and ketamine cream in treating peripheral neuropathy caused by chemotherapy in patients with cancer http://clinicaltrials.gov
   Google Scholar
• ClinicalTrials.gov. NCT00313378 effects of perioperative systemic ketamine on development of long-term neuropathic pain after thoracotomy http://clinicaltrials.gov
   Google Scholar
• ClinicalTrials.gov. NCT00961194, oral ketamine administration in patients with peripheral neuropathic pain (KETACLUD) http://clinicaltrials.gov
   Google Scholar
• NCT00475904, a domparison of EpiCept™ NP-1 topical cream vs. oral gabapentin in postherpetic neuralgia http://clinicaltrials.gov
   Google Scholar
• PAION And ERGOMED report full data of CNS 5161 Phase IIa study in neuropathic cancer pain www.medicalnewstoday.com/articles/145969.php
   Google Scholar
• ClinicalTrials.gov. NCT00258622, NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain http://clinicaltrials.gov
   Google Scholar
• Neurotune. Therapeutic Areas www.neurotune.com/therapeutic/neuropathic.htm
   Google Scholar
• ClinicalTrials.gov. NCT00838799, study of the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain http://clinicaltrials.gov
   Google Scholar
• Evotec AG. Evotec successfully completes Phase I for potential Alzheimer’s Disease and neuropathic pain treatment, EVT 101 www.evotec.com
   Google Scholar
• TorreyPines Therapeutics Inc. First multiple dose clinical trial of TorreyPines therapeutics’ oral compound NGX426 demonstrates compound is safe and well-tolerated www.torreypinestherapeutics.com
   Google Scholar
• NeuroSearch. NeuroSearch announces results from Phase II studies of ABT-894 in diabetic neuropathic pain. February 11, 2009 www.neurosearch.com
   Google Scholar
• Nutra Pharma Corp. Nutra Pharma announces final approval to begin Phase IIb human clinical trial for the treatment of adrenomyeloneuropathy www.NutraPharma.com
   Google Scholar
• Targacept Inc. Targacept Provides Update on TC-6499 and Pain Program in GlaxoSmithKline Alliance www.targacept.com
   Google Scholar